Litcius/Paper detail

Use and Perceptions of Cannabidiol Products in Canada and in the United States

Samantha Goodman, Elle Wadsworth, Gillian L. Schauer, David Hammond

2020Cannabis and Cannabinoid Research110 citationsDOIOpen Access PDF

Abstract

Objectives: This study aimed to characterize use and perceptions of cannabidiol (CBD) products. Materials and Methods: Participants aged 16–65 years in Canada ( n =15,042) and the United States ( n =30,288) completed measures on prevalence and patterns of CBD product use and perceptions of CBD oil as part of the 2019 International Cannabis Policy Study online survey. Results: Past 12-month CBD product use was significantly more prevalent among respondents in the United States (26.1%) than in Canada (16.2%). Consumers in the United States and Canada reported using a range of CBD products, including drops (46.3% vs. 47.3%, respectively), topicals (26.0% vs. 16.7%), edibles/foods (23.8% vs. 17.6%), vape oils (18.9% vs. 13.3%), capsules (13.3% vs. 16.7%), and dried flower (10.1% vs. 16.1%). CBD was most commonly reported for management of pain, anxiety, and depression. Over half of CBD consumers in both countries reported that CBD oil was beneficial for health. Conclusions: Use of CBD products is common in both the United States and Canada, primarily to manage self-reported health conditions for which there is little or no evidence of efficacy. Clearer public health messaging regarding the therapeutic effects of CBD is warranted.

Topics & Concepts

CannabidiolMedicineCannabisDepression (economics)Environmental healthPublic healthAnxietyTobacco productFamily medicinePsychiatryNursingMacroeconomicsEconomicsCannabis and Cannabinoid ResearchReligion, Spirituality, and PsychologyDiet, Metabolism, and Disease